Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

203.49 +2.76 (+1.37%)
Official Closing Price Updated: 4:10 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,049,289
Open 199.78
Bid (Size) 202.00 (100)
Ask (Size) 205.00 (100)
Prev. Close 200.73
Today's Range 199.23 - 204.34
52wk Range 182.39 - 212.71
Shares Outstanding N/A
Dividend Yield 0.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
From AstraZeneca
Via Business Wire

Performance

YTD
+8.0%
+8.0%
1 Month
-0.1%
-0.1%
3 Month
+8.0%
+8.0%
6 Month
+8.0%
+8.0%
1 Year
+8.0%
+8.0%

More News

Read More
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
Via MarketMinute
Topics Intellectual Property
News headline image
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
From AstraZeneca
Via Business Wire
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Could This International ETF Be One of the Best Investments of 2026? ↗
Via The Motley Fool
Topics ETFs
News headline image
The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis
Via MarketMinute
Topics Artificial Intelligence Earnings Regulatory Compliance
News headline image
The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
Via MarketBeat
Topics ETFs
News headline image
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
Via MarketMinute
Topics ETFs
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
From AstraZeneca
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 203.49
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 04/02/26 04:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.